KEI Comments Regarding the NIST Special Publication 1234 Draft Green Paper on Return on Public Investment

KEI filed comments on the NIST Draft Green paper on the return from investment on federally funded R&D (See: https://www.keionline.org/29518). We expect the comment period to be extended, but filed this on January 9, 2018, as an initial submission. KEI-comments-NIST-SP-1234-ROI-9Jan2018… Continue Reading

2019: Joint Comments on NIH Prospective License to Medigen on RSV and Parainfluenza Vaccines

On January 7, 2019, KEI and MSF (Doctors Without Borders/Médecins Sans Frontières USA) submitted comments to the Federal Register notice (83 FR 65696) on the “Prospective Grant of Exclusive Patent License: Production of Live Respiratory Syncytial Virus and Parainfluenza Virus… Continue Reading

2019: Joint Comments on NIH Prospective License to Sixfold Biosciences on Nanoparticles Technology

On Monday January 7, 2019, KEI submitted joint comments on behalf of Health GAP, Social Security Works, the Union for Affordable Cancer Treatment, and Professor Brook Baker of Northeastern University to the Federal Register notice (83 FR 65694) for the”Prospective… Continue Reading

2018: KEI comments on Navy proposed exclusive license to Vedevo for data compression patent

Office of Research and Technology Applications, Naval Postgraduate School, Research and Sponsored Programs Office, NPS Code 41, 699 Dyer Road, Bldg. HA, Room 226, Via. Ms. Deborah Buettner, Director, Research and Sponsored Programs Office, email: dbuettne@nps.edu Dear Deborah Beuttner, We… Continue Reading

2018: Comments on NIH license to Bull Run Capital, Inc. for safer non-lethal antagonist

Jaime M. Greene Senior Licensing and Patenting Manager NCI Technology Transfer Center Email: greenejaime@mail.nih.gov December 16, 2018 Re: Comments on “Prospective Grant of an Exclusive Patent License: Agonist/Antagonist Compositions and Methods of Use for certain inventions” (83 FR 61659) Dear… Continue Reading

KEI Intent to Testify and Testimony Summary/Comments on Negotiating Objectives for a U.S.-European Union Trade Agreement (USEUTA)

DATE: December 10, 2018 Intent to Testify and Testimony Summary/Comments on Negotiating Objectives for a U.S.-European Union Trade Agreement (USEUTA) Luis Gil Abinader. Knowledge Ecology International 1621 Connecticut Avenue, Northwest, Suite 500, Washington, DC 20009. Phone number +1.202.332.2670. Federal Register… Continue Reading

2018: NIH Prospective Grant of an Exclusive Patent License to ElevateBio for CAR T cancer treatment

The following are comments by KEI, UACT, Social Security Works, HealthGap, Public Citizen, Dr. Ophira Ginsbug and James Love on an NIH proposed exclusive license for patents on a CAR T technology for “Treatment of FMS-Like Tyrosine Kinase 3 (FLT3)… Continue Reading